CO2019011271A2 - Análogos de deutetrabenazina, su preparación y uso - Google Patents

Análogos de deutetrabenazina, su preparación y uso

Info

Publication number
CO2019011271A2
CO2019011271A2 CONC2019/0011271A CO2019011271A CO2019011271A2 CO 2019011271 A2 CO2019011271 A2 CO 2019011271A2 CO 2019011271 A CO2019011271 A CO 2019011271A CO 2019011271 A2 CO2019011271 A2 CO 2019011271A2
Authority
CO
Colombia
Prior art keywords
deutetrabenazine
analogs
preparation
compositions
same
Prior art date
Application number
CONC2019/0011271A
Other languages
English (en)
Spanish (es)
Inventor
Chengzi Zhang
Jim Kerr
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of CO2019011271A2 publication Critical patent/CO2019011271A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Machine Translation (AREA)
  • Pens And Brushes (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
CONC2019/0011271A 2017-03-15 2019-10-10 Análogos de deutetrabenazina, su preparación y uso CO2019011271A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762471484P 2017-03-15 2017-03-15
PCT/US2018/022562 WO2018170214A1 (en) 2017-03-15 2018-03-15 Analogs of deutetrabenazine, their preparation and use

Publications (1)

Publication Number Publication Date
CO2019011271A2 true CO2019011271A2 (es) 2020-02-28

Family

ID=61873991

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0011271A CO2019011271A2 (es) 2017-03-15 2019-10-10 Análogos de deutetrabenazina, su preparación y uso

Country Status (20)

Country Link
US (4) US11813232B2 (enExample)
EP (1) EP3596077A1 (enExample)
JP (3) JP7608050B2 (enExample)
KR (2) KR20200003791A (enExample)
CN (1) CN110709398A (enExample)
AR (1) AR111182A1 (enExample)
AU (2) AU2018236336B2 (enExample)
BR (1) BR112019018966A2 (enExample)
CA (1) CA3056612A1 (enExample)
CL (1) CL2019002629A1 (enExample)
CO (1) CO2019011271A2 (enExample)
EA (1) EA201992168A1 (enExample)
IL (1) IL269132A (enExample)
MX (1) MX2019010913A (enExample)
PE (1) PE20191819A1 (enExample)
SG (1) SG11201908477QA (enExample)
TW (1) TWI772382B (enExample)
UA (1) UA127052C2 (enExample)
WO (1) WO2018170214A1 (enExample)
ZA (1) ZA201906326B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11813232B2 (en) 2017-03-15 2023-11-14 Auspex Pharmaceuticals, Inc. Analogs of deutetrabenazine, their preparation and use
WO2020123900A1 (en) 2018-12-13 2020-06-18 Auspex Pharmaceuticals, Inc. Deutetrabenazine for the treatment of dyskinesia in cerebral palsy
WO2020165807A1 (en) * 2019-02-14 2020-08-20 Dr. Reddy's Laboratories Limited Solid forms of deutetrabenazine and process for the preparation thereof
US12599598B2 (en) 2020-06-10 2026-04-14 Auspex Pharmaceuticals Llc Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
EP4153136B1 (en) * 2020-06-10 2024-01-10 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2081929T3 (da) 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse
CA2736409C (en) * 2008-09-18 2017-07-11 Auspex Pharmaceutical, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2801061A1 (en) 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
WO2012081031A1 (en) * 2010-12-15 2012-06-21 Enaltec Labs Pvt. Ltd. Process for preparing tetrabenazine
US9550780B2 (en) * 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2883641C (en) * 2012-09-18 2021-09-14 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CN105873589B (zh) 2013-12-03 2019-11-01 奥斯拜客斯制药有限公司 制造苯并喹啉化合物的方法
CN114767672A (zh) 2015-03-06 2022-07-22 奥斯拜客斯制药有限公司 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物
US11813232B2 (en) 2017-03-15 2023-11-14 Auspex Pharmaceuticals, Inc. Analogs of deutetrabenazine, their preparation and use

Also Published As

Publication number Publication date
AU2018236336B2 (en) 2022-02-24
NZ757789A (en) 2024-08-30
US11179386B2 (en) 2021-11-23
AR111182A1 (es) 2019-06-12
KR20200003791A (ko) 2020-01-10
CA3056612A1 (en) 2018-09-20
US11813232B2 (en) 2023-11-14
EA201992168A1 (ru) 2020-03-16
AU2022203369B2 (en) 2024-04-04
US20180263972A1 (en) 2018-09-20
EP3596077A1 (en) 2020-01-22
CN110709398A (zh) 2020-01-17
AU2018236336A1 (en) 2019-10-24
SG11201908477QA (en) 2019-10-30
KR20230003308A (ko) 2023-01-05
TWI772382B (zh) 2022-08-01
MX2019010913A (es) 2020-01-20
US12502385B2 (en) 2025-12-23
PE20191819A1 (es) 2019-12-27
CL2019002629A1 (es) 2020-01-24
ZA201906326B (en) 2022-12-21
AU2022203369A1 (en) 2022-06-09
US20220040170A1 (en) 2022-02-10
JP2024050724A (ja) 2024-04-10
US20220088006A1 (en) 2022-03-24
UA127052C2 (uk) 2023-03-29
US20200016148A1 (en) 2020-01-16
TW201840317A (zh) 2018-11-16
JP2020510073A (ja) 2020-04-02
JP7631572B2 (ja) 2025-02-18
JP7608050B2 (ja) 2025-01-06
JP2023010754A (ja) 2023-01-20
IL269132A (en) 2019-11-28
BR112019018966A2 (pt) 2020-04-22
WO2018170214A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
CL2023001911A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
MX2017007585A (es) Anticuerpos anti-c10orf54 y usos de los mismos.
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
CO2019012957A2 (es) Inhibidores de quinasa y usos de los mismos
CR20180320A (es) Compuestos inhibidores de la quinasa de union a tank
CL2017003356A1 (es) Moduladores cot y métodos de uso de los mismos
CR20160419A (es) Nuevos compuestos biciclicos
DOP2017000298A (es) Reguladores de nrf2
NI201400125A (es) Antagonistas de st2l y métodos de uso
CR20150436A (es) Nuevos octahidro-pirrolo[3,4-c]-pirrol y -piridina-fenilo
DOP2015000219A (es) Compuestos de heteroarilo y sus usos
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
CL2019002629A1 (es) Análogos de deutetrabenazina, su preparación y uso.
UY37410A (es) Antagonistas de trpv4
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
MX2021006977A (es) Anellosomas y metodos de uso.
UY37015A (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
MX2018007084A (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
CR20170076A (es) Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
UY38031A (es) Hidroxiisoxazolinas y derivados de estos
CR20170102A (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
MX2017000862A (es) Formulacion de factor viii.
MX2016003215A (es) Preparacion y uso de una composicion para la prevencion y mitigacion de los efectos de la radiacion.
UY34761A (es) Composiciones parasiticidas que comprenden derivados de benzimidazol, métodos y usos de los mismos.